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Abstract 
Background: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after 
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to pre-
dict outcomes beyond known clinical and pathological prognostic features.
Methods: Fifteen patients with relapsed PMP and progressive disease within the last 6 months were included and 
received metronomic capecitabine (625 mg/mq/day b.i.d.) and bevacizumab (7.5 mg/Kg three-weekly) until pro-
gressive disease/unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Ion Torrent® next 
generation sequencing technology (Hot-spot Cancer Panel) was used to characterize molecular features.
Results: At a median follow up of 12 months, median PFS was 8.2 months and 1-year overall survival was 91 %. Par-
tial responses were observed in 20 % of cases, but a significant reduction of tumor markers in up to 79 %. Treatment 
was very well tolerated without no new safety signals. All tumor samples except one had KRAS mutations. Patients 
with GNAS mutations had a significantly shorter median PFS as compared to GNAS wild-type ones (5.3 months vs. not 
reached; p < 0.007). The results were externally validated on our previous series of PMP patients. GNAS mutations were 
rare in a parallel cohort of 121 advanced colorectal cancers (2.5 %), but were associated with peculiar clinical-patho-
logical features and aggressive course.
Conclusions: Metronomic capecitabine and bevacizumab is an active and well tolerated option in patients with 
relapsed PMP. The negative prognostic effect of GNAS mutations in gastrointestinal cancers warrants further confirma-
tory studies and may prompt the development of effective targeted strategies.
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Background
Pseudomyxoma peritonei (PMP) has an incidence of 1–2 
per million/year, and consists in accumulation of muci-
nous peritoneal implants usually arising from appendi-
ceal neoplasms [1]. Independently from its low or high 
histological grade [2, 3], PMP is initially managed with 
cytoreductive surgery (CRS) and hyperthermic intra-
peritoneal chemotherapy (HIPEC), with the goal of extir-
pating both gross and microscopic disease, respectively. 
This approach confers a 20-years overall survival (OS) 
greater than 70 % [4, 5], comparing favourably with his-
torical controls. However, a significant proportion of 
patients will ultimately die of loco-regional disease pro-
gression [5]. While repeated CRS may confer some ben-
efit to selected patients, there is a lack of evidence about 
systemic treatment of unresectable or relapsed PMP. 
Despite a borderline malignant potential and low prolif-
eration index, non-randomized series reported encour-
aging results with fluoropyrimidine-based combination 
chemotherapy [6, 7].
The anti-vascular endothelial growth factor (VEGF) 
monoclonal antibody bevacizumab is routinely used in 
advanced colorectal cancer, as well as in peritoneal car-
cinomatosis secondary to ovarian cancer [8, 9]. Metro-
nomic therapy with low-dose continuous administration 
of chemotherapy in combination with bevacizumab may 
be effective in colorectal and ovarian cancers [10, 11]. 
Bevacizumab and metronomic capecitabine may have 
synergic antiangiogenic, immunomodulatory and cyto-
static effects, being a useful strategy for slow-growing 
and relatively resistant tumors such as PMP.
In this mono-institutional study, we aimed at assess-
ing the efficacy and safety of metronomic capecitabine 
and bevacizumab as palliative treatment of patients with 
relapsed PMP.
Patients and methods
Patients
Patients with low or high-grade PMP of appendiceal ori-
gin were eligible. Inclusion criteria were: age ≥18 years; 
disease relapse following CRS and HIPEC, AND pro-
gressive disease (PD) assessed by computed tomography 
scan during the last 6 months; ECOG performance status 
0–1; adequate bone marrow, hepatic, and renal functions. 
Exclusion criteria were: prior systemic chemotherapy; 
plan of repeated surgery in case of response to treatment 
or after a neoadjuvant treatment phase; uncontrolled 
hypertension; clinically significant cardiovascular dis-
ease; coagulopathy; history of malignancy in the previous 
3 years.
The study was conducted according to Good Clini-
cal Practices and was approved by the local ethics 
committee (study INT 14/14). All subjects provided writ-
ten informed consent prior to study procedures.
Study flowchart
Patients received oral capecitabine 625  mg/sqm/day 
(≥70  years: 500  mg/mq/day) b.i.d. plus intravenous 
three-weekly bevacizumab 7.5  mg/kg, until progressive 
disease or unacceptable toxicity.
The primary study endpoint was progression-free 
survival (PFS). Secondary endpoints were: OS; overall 
response rate (ORR) according to RECIST vers. 1.1 crite-
ria. [12]; tumor markers response; safety.
Baseline evaluations included the following: semiology; 
full blood tests; electrocardiogram; computed tomog-
raphy (CT) scan of the chest and abdomen; all circulat-
ing tumor markers CEA, CA 19-9, CA 125 and CA15-3. 
During treatment, adverse events (AEs) were assessed 
according to NCI-CTC vers. 4.03 [13]. CT scans and 
tumor markers were repeated every 12 weeks until PD.
Biomarkers evaluation
Formalin-fixed paraffin-embedded tissues of peritoneal 
deposits were reviewed for tumor content and manually 
microdissected to isolate a high percentage of neoplastic 
cells. DNA was isolated using the GeneRead DNA FFPE 
kit (Qiagen, Hilden, Germany, http://www.qiagen.com 
Cat. n. 180134). Next generation sequencing of 50 genes’ 
hotspot regions included in the Hotspot Cancer Panel v2 
(Life Technologies) was then performed by using the Ion 
Torrent Personal Genome Machine platform (Life Tech-
nologies) [14]. Additionally, MGMT promoter methylation 
status was assessed by methylation specific polymerase 
reaction, as previously described [15]. MET amplification 
status was assessed by bright field dual-color SISH analysis 
(Ventana Medical Systems) in at least 40 non overlapping 
nuclei; MET expression by using a rabbit monoclonal anti-
MET antibody (dilution 1:200; clone SP44, Spring Biosci-
ence, Pleasanton, CA) (Additional file 1: Methods S1) [16].
Statistical analysis
The study was designed to show non–inferiority toward 
historical experience, in which median progression free 
survival is around 8 months. Accordingly, non-inferiority 
of the experimental treatment was inferred if the lower 
boundary of the 95 % confidence interval (CI) exceeded 
5  months, a threshold clearly denoting a detrimental 
effect. With this rule, we estimated that a sample size of 
15 patients yields 80  % power in case of a median PFS 
of 10  months, a value chosen to reflect a hypothetical 
improvement with the experimental treatment.
All time-to-event parameters were calculated by the 
Kaplan–Meier method. Median values were calculated 
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and presented with 95 % confidence intervals. Data were 
analysed using the SAS System for Windows, version 9.2.
Results
Patients population
From February 2014 to July 2015, fifteen patients were 
included. The data lock was in October 2015. Baseline 
demographic and disease characteristics are shown in 
Table 1. Briefly, one-third of the patients had high grade 
histology and 47 % had relapse within 1 year from CRS/
HIPEC. All patients except one had baseline elevation of 
at least one tumor marker.
Efficacy outcomes
At a median follow-up of 12  months (range 3–18), 8 
(53  %) patients had PD and only 2 died. The primary 
endpoint was not inferior to historical controls, with 
a median PFS of 8.2  months (95  % CI 5.3-not assess-
able). Obviously, median OS was not reached, since the 
1-year OS rate was 91 % (95 % CI, 75 %-100 %). Kaplan–
Meier curves for PFS and OS of the study population 
are depicted in Figs.  1 and 2, respectively. Concerning 
secondary endpoints of activity, three patients had a PR, 
accounting for an ORR of 20 %. At the time of this analy-
sis, two responses were still ongoing (12+ months and 
18+ months). Ten (67  %) patients had a SD and only 2 
(13 %) had early PD. Clinical benefit rate (CR + PR + SD) 
was 87 %. Reductions of in the tumour marker levels by 
more than 30 % were recorded for 11 (79 %) of 14 evalu-
able patients. 
Safety outcomes
All patients received at least one treatment cycle and 
were evaluable for safety. Median number of cycles was 
6 (range 3–18). The percentages of patients who expe-
rienced at least one AE were: 53 % (grade 3 or 4: 13 %). 
Table  2 depicts the frequency of all grades of AEs dur-
ing treatment. Treatment discontinuation related to seri-
ous AEs was reported in 1 case, while dose reductions 
of capecitabine were performed in only 2 cases. The 
only treatment-related grade 3/4 AEs were hyperten-
sion, thromboembolism and hand-foot syndrome—while 
other AEs were mild to moderate (mainly diarrhoea and 
fatigue).
Biomarkers
As shown in Table 3, all 15 peritonectomy samples were 
available. In the next-generation sequencing analysis, 
sequence reads were filtered for quality: in the variant 
caller plugin, we included the variant that had a quality 
score at least 20. Eighty-five percent of the bases called 
Table 1 Patients and disease characteristics
CRS cytoreductive surgery; HIPEC hyperthermic intraperitoneal chemotherapy; 
PCI peritoneal carcinomatosis index; CC completeness of cytoreduction score
Main characteristics (N = 15) N° (%)
Age, years
 Median (range) 52 (42–68)
Sex
 Male 9 (60)
 Female 6 (40)
ECOG performance status
 0 12 (80)
 1 3 (20)
Histological grade
 High 5 (33)
 Low 10 (67)
Time from CRS + HIPEC to relapse
 Median (range, months) 13 (5–36)
 ≤12 months 7 (47)
 >12 months 8 (53)
PCI at the time of CRS + HIPEC
 Median (range) 27 (8–39)
Completeness of cytoreduction
 CC-0 8 (53)
 CC-1 7 (47)
Fig. 1 Kaplan–Meier curve for progression-free survival
Fig. 2 Kaplan–Meier curve for overall survival
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by PGM have quality phred-scores of Q30 (A phred score 
of Q30 corresponds to a probability of base-call error of 
1 in 1000 or 99.9 % accuracy). For all sample, the average 
base coverage depth was at least 1500× and uniformity at 
least 94 %.
Given the low cellularity of these tumors, the Nor-
manno et  al. [17] heterogeneity score of each mutation 
was too wide to allow comparisons with colorectal can-
cer NGS data. All tumors except one (93  %) had KRAS 
exon 2 mutations (80 % in codon 12; 13 % in codon 13), 
while no NRAS or BRAF mutations were detected. GNAS 
mutations were found in 9 (60 %). No significant associa-
tions between GNAS mutations and the clinic-patholog-
ical variables (including age, gender, ECOG performance 
status, histological grade, time elapsed from surgery to 
relapse, PCI and completeness of cytoreduction) were 
found. However, median PFS was significantly shorter 
in patients with GNAS mutations as compared to those 
with GNAS wild-type status (5.3  months versus not 
reached; Hazard Ratio [HR] for progression 7.57, 95  % 
CI, 1.73–33.20; log-rank test p = 0.007; Fig. 3). The two 
tumors with early PD had a GNAS mutation. In attempt 
to externally validate GNAS mutations as prognostic, we 
explored their interaction with PFS in FOLFOX-4 treated 
patients included in our previous paper [6]. Of 11 avail-
able samples, GNAS mutations were found in 6 (55  %), 
were not associated with clinic-pathological variables, 
but maintained a similar prognostic effect (log-rank test 
p = 0.002; Additional file 2: Figure S1). Coupling together 
the two series, we obtained a pooled dataset of 26 
patients, of whom 15 (58 %) had a GNAS mutation. We 
were able to confirm that median PFS was significantly 
shorter in patients with GNAS mutation as compared to 
those with GNAS wild-type status (5.1 versus 13 months; 
HR for progression 11.26, 95  % CI 3.62–35.06; log-rank 
test p < 0.0001; Additional file 3: Figure S2).
Regarding ancillary data, TP53 mutations were found 
in 3 (20  %) samples, while HNF1A was mutated in 1 
case, and FGFR3 plus LKB1 were found concomitantly 
mutated in a patient with long-lasting benefit. MGMT 
promoter methylation was found in 3 (20  %) samples. 
MET gene was never amplified and MET protein was 
overexpressed in 2 (13 %) cases.
Finally, we sought to investigate the role of GNAS 
mutations in patients with metastatic colorectal cancer. 
By using the same next generation sequencing technol-
ogy (Ion Torrent®) in a retrospective mono-institutional 
series of 121 cases, we found GNAS mutation in only 3 
(2.5  %). Surprisingly, all cases shared the same peculiar 
clinical and pathological features: right side origin, muci-
nous histology, synchronous peritoneal metastases and 
concomitant KRAS mutations. Additionally, all three 
patients had a PD as best response to both FOLFOX and 
FOLFIRI regimens, even when combined with bevaci-
zumab (Additional file 4: Table S1).
Discussion
In patients with unresectable or recurrent PMP of appen-
diceal origin, fluoropyrimidine-based combination 
chemotherapy may be helpful for palliation of symptoms 
and slowing disease progression [17]. In a prospec-
tive cohort of 20 patients treated with FOLFOX-4 regi-
men, we obtained an ORR of 20 % and a median PFS of 
8  months [6]. A previous phase II study evaluated the 
combination of capecitabine with mitomycin-C, even 
if only 22 evaluable patients had progressive disease at 
baseline [7]. In this subgroup, ORR was 14 %, while PFS 
was not reported. This scenario raises two fundamental 
issues. First, the improvement of medical treatment of 
this orphan disease is an urgent and unmet clinical need. 
Second, the availability of robust evidences is limited 
by the rarity of the disease, the heterogeneity of clini-
cal, pathological and biological features, and variability 
of natural history—ranging from an extremely indolent 
course (for which watchful waiting is still a valid option) 
to a frankly malignant one. In our study, all patients had 
progressive disease within 6 months prior to study entry, 
and not surprisingly showed a significant proportion of 
adverse prognostic features, such as high grade histology 
or time to relapse from CRS and HIPEC <12 months. The 
combination of metronomic capecitabine and bevaci-
zumab achieved results comparable to prior experiences, 
since ORR was 20  % and median PFS was 8.2  months. 
Importantly, the safety profile was extremely favour-
able, making the combination as a valuable treatment 
option with a good therapeutic index. The reasons for 
investigating this combination were several. First, the 
possibility to continue treatment until PD with minimal 
chronic toxicity is a fundamental difference with oxalipl-
atin- or mitomycin-C-based combinations [18]. Second, 
metronomic therapy may be active through multiple 
Table 2 Treatment-related toxicity
NCI-CTC, National Cancer Institute—Common Toxicity Criteria
Adverse events N° of patients (%) grade according NCI-
CTC vers. 4.03
G1 G2 G3 G4
Hypertension – 1 (6 %) 1 (6 %) –
Thromboembolic event – 1 (6 %) 1 (6 %) –
Diarrhea 2 (13 %) 1 (6 %) – –
Neutropenia – 1 (6 %) – –
Hand Foot Syndrome – 1 (6 %) 1 (6 %) –
Epistaxis 1 (6 %) – – –
Fatigue 2 (13 %) – – –
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mechanisms, such as restoring of anticancer immune 
response, induction of tumor dormancy, and targeting 
tumor angiogenesis [19–23]. Finally, especially consid-
ering slow-proliferating tumors such as PMP, the met-
ronomic schedule of capecitabine administration may 
achieve a long-lasting cytostatic effect and synergize with 
anti-VEGF agents, such as bevacizumab [24].
We shared new insights into the molecular landscape 
of PMP and appendiceal cancers [25]. First, the identi-
fication of new treatment targets in this orphan disease 
is strictly dependent on a better knowledge of its bio-
logical features. Second, clinicians should be aware the 
natural history of PMP is not only influenced by vali-
dated prognostic factors [5, 26, 27]—such as complete-
ness of cytoreduction, peritoneal carcinomatosis index 
and histological grade—but also by potential prognostic 
biomarkers linked to disease aggressiveness. The preva-
lence of GNAS mutations in our study was in line with 
the literature data [28, 29]. Exploiting our homogeneous 
data-set, we were able to show for the first time a poten-
tial prognostic effect of such mutations following disease 
relapse and palliative treatment with fluoropyrimidine-
based chemotherapies. Interestingly, we confirmed a low 
prevalence (2.5 %) of GNAS mutations in colorectal can-
cer, similarly to what was previously described [30]. How-
ever, our retrospective large cohort of patients seemed to 
identify GNAS-mutated colorectal cancer as associated 
with aggressive clinical course and phenotypic charac-
teristics resembling to PMP (right side origin, mucinous 
histology, peritoneal involvement and concomitant KRAS 
mutations). However, evidence on the pathogenetic and 
prognostic role of GNAS mutations in colorectal cancer 
cannot be considered definitive given their rarity and the 
retrospective nature of our data.
We confirmed that the prevalence of KRAS mutations 
in PMP was among the highest in human pathology, as 
highlighted by previous studies using highly sensitive 
techniques [28]. However, in the largest available series 
of PMP, KRAS mutations were not prognostic following 
curative surgery [31]. It is important to point out that 
the classical histology of PMP is constituted by sparse 
neoplastic cells within a background of abundant muci-
nous deposits. Thus, standard direct DNA sequencing 
techniques may be not sensitive enough to detect low 
amounts of cells harbouring mutations and may repre-
sent the cause of frequent false negative results. Mutant-
enriched polymerase chain reaction or next-generation 
sequencing methods may allow the detection of low lev-
els of mutant DNA against a background of wild-type 
sequence and is of particular value for the molecular 
characterization of tumors with low cellularity such as 
PMP [28, 31, 32]. Not surprisingly, the Normanno et al. 
[17] heterogeneity score was quite wide in our samples.
Our study has some obvious limitations. Both the small 
sample size and lack of randomization make impossi-
ble to quantify the relative benefits from the addition of 
bevacizumab to fluoropyrimidines. For the same reasons, 
it is impossible to distinguish between the poor prognos-
tic effect of GNAS mutations and their potential value as 
predictive biomarker of treatment resistance.
In conclusion, metronomic capecitabine and beva-
cizumab is an active and well tolerated combination in 
patients with relapsed PMP. The negative prognostic 
effect of GNAS mutations warrants further confirmatory 
studies and may prompt the development of effective tar-
geted strategies.
Conclusions
In this study, 15 patients with relapsed and progressive 
peritoneal pseudomyxoma were treated with metro-
nomic capecitabine and bevacizumab, achieving a 20  % 
response rate and a 8.2 months progression-free survival. 
A next-generation sequencing approach identified GNAS 
mutations as prognostic biomarker in this homogene-
ous population. Patients with GNAS mutations had sig-
nificantly poorer outcome in terms of progression-free 
survival.
This observation was externally validated in a previ-
ous patients series of peritoneal pseudomyxoma patients 
treated with FOLFOX-4 chemotherapy. Additionally, 
the prognostic role of GNAS was also explored in a ret-
rospective data-set of 121 advanced colorectal cancers: 
GNAS mutations seemed to identify a new and rare 
molecular subtype with unfavorable outcome and pecu-
liar clinical and pathological characteristics—such as 
right side origin, mucinous histology, peritoneal involve-
ment and concomitant KRAS mutation.
Fig. 3 Comparison of Kaplan-Meier curves for progression-free sur-
vival according to GNAS mutational status in the prospective cohort 
(metronomic capecitabine and bevacizumab)
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